Back

In vivo gene editing with YOLT-201 for transthyretin amyloid cardiomyopathy – an open-label, first-in-human clinical trial

31 August 2026 (09:40 - 09:50)
Organised by: Logo
Congress Presentation Part of: Improving care in cardiac amyloidosis Infiltrative Myocardial Disease ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Mrs Hui Yan

First affiliated Hospital at Zhejiang University School of Medicine, Hangzhou (China)

5 More presentations in this session

Presentation thumbnail
Novel blood-based biomarkers for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) in patients heart failure with preserved ejection fraction
Doctor H. Gaggin (Boston, US)
Abstract
Presentation thumbnail
Assessing generalizability of an AI model for cardiac amyloidosis detection in ECGs: interim results of a multi-centre, external validation study
Assistant Professor F. Ahmad (Chicago, US)
Abstract
Presentation thumbnail
Cardiac presentation and treatment response by sex in patients with transthyretin amyloidosis: pooled analysis of vutrisiran and patisiran phase 3 studies
Assistant Professor A. Zaroui (Creteil, FR)
Abstract
Presentation thumbnail
Prognostic value of CT-derived pectoralis muscle area in tafamidis-treated ATTRwt cardiomyopathy
Doctor K. Ayai (JP)
Abstract
Presentation thumbnail
Recurrence of transthyretin amyloid cardiomyopathy following heart transplantation - a long term follow-up analysis
Doctor M. Poledniczek (Vienna, AT)
Abstract

Access the full session

Session thumbnail
Improving care in cardiac amyloidosis

The Event

Event poster

ESC Congress 2026

31 August 2026 09:40 CET
You may be interested in
thumbnail
Congress Presentation
Transthyretin-directed antisense oligonucleotide therapy effects on ATTRv myocardiopathy
20 May 2023
thumbnail
Congress Presentation
Durability of Effects of CTX310, a CRISPR-Cas9 Gene Editing Targeting ANGPTL3
28 August 2026
thumbnail
Congress Presentation
Active-target liposomal drug shows significant atherosclerotic plaque regression effect: a proof-of-concept phase 1b/2a clinical trial
1 September 2025
thumbnail
Congress Presentation
Safety and clinical effects of sodium-glucose cotransporter-2 inhibitors in transthyretin amyloid cardiomyopathy
21 May 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources